MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Overview Fund Activity
Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings
 

About: Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Employees: 593

Healthcare Drug Manufacturers - General

Financial journalist opinion

Negative
Finbold
1 year ago
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
How this insider trader nailed every single stock trade
Positive
Zacks Investment Research
1 year ago
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
Neutral
PRNewsWire
1 year ago
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Positive
CNBC
1 year ago
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Positive
Zacks Investment Research
1 year ago
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
See News Rankings
Charts implemented using Lightweight Charts™